PMPaolo Mezzelani

Paolo Mezzelani

*This is an algorithmically generated author record based on publicly available information.

Paolo Mezzelani has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bloodborne Viral Hepatitis Infections among Drug Users: The Role of Vaccination

    by Fabio Lugoboni, Gianluca Quaglio, Paolo Civitelli, Paolo Mezzelani

    Drug use is a prevalent world-wide phenomenon and hepatitis virus infections are traditionally a major health problem among drug users (DUs). HBV and HCV, and to a lesser extent HAV, are easily transmitted through exposure to infected blood and body fluids. Viral hepatitis is not inevitable for DUs. Licensed vaccines are available for hepatitis A and hepatitis B. The purpose of this overview is to show some epidemiological data about HBV and the other blood-borne viral hepatitis among DUs and to summarize and discuss use of hepatitis vaccinations in this population. Successful vaccination campaigns among DUs are feasible and well described. We try to focus on the most significant results achieved in successful vaccination programs as reported in scientific literature. Vaccination campaigns among DUs represent a highly effective form of health education and they are cost-saving.


  • Open Access

    Patients in long-term maintenance therapy for drug use in Italy: analysis of some parameters of social integration and serological status for infectious diseases in a cohort of 1091 patients

    by Gianluca Quaglio, Fabio Lugoboni, Cristian Pattaro, Gics, Linda Montanari, Alessandro Lechi, Paolo Mezzelani, Don C Des Jarlais

    Heroin addiction often severely disrupts normal social functioning. The aims of this multi-centre study of heroin users in long-term replacement treatment were: i) to provide information on aspects of social condition such as employment, educational background, living status, partner status and any history of drug addiction for partners, comparing these data with that of the general population; ii) to assess the prevalence of hepatitis, syphilis and HIV, because serological status could be a reflection of the social conditions of patients undergoing replacement treatment for drug addiction; iii) to analyse possible relationships between social conditions and serological status. A cross-sectional study was carried out in sixteen National Health Service Drug Addiction Units in northern Italy. The data were collected from February 1, 2002 to August 31, 2002. Recruitment eligibility was: maintenance treatment with methadone or buprenorphine, treatment for the previous six months, and at least 18 years of age. In the centres involved in the study no specific criteria or regulations were established concerning the duration of replacement therapy. Participants underwent a face-to-face interview. The conditions of 1091 drug treatment patients were evaluated. The mean duration of drug use was 14.5 years. Duration was shorter in females, in subjects with a higher educational background, and in stable relationships. Most (68%) had completed middle school (11–14 years of age). Seventy-nine percent were employed and 16% were unemployed. Fifty percent lived with their parents, 34% with a partner and 14% alone. Males lived more frequently with their parents (55%), and females more frequently with a partner (60%). Sixty-seven percent of male patients with a stable relationship had a partner who had never used heroin. HCV prevalence was 72%, HBV antibodies were detected in 42% of patients, while 30% had been vaccinated; 12.5% of subjects were HIV positive and 1.5% were positive for TPHA. A significant percentage of heroin users in treatment for opiate addiction in the cohort study have characteristics which indicate reasonable integration within broader society. We posit that the combination of effective treatment and a setting of economic prosperity may enhance the social integration of patients with a history of heroin use.


  • Open Access

    Prevalence of hepatitis A among drug users in north-eastern Italy

    by Fabio Lugoboni, Gianluca Quaglio, Benedetta Pajusco, Maurizio Foroni, Gianstefano Blengio, Giorgio Talamini, Paolo Mezzelani, Don C. Des Jarlais

    Background: The authors report on the prevalence of, and risk factors for, hepatitis A virus (HAV) in a group of drug users in Italy. Methods: 404 heroin users were recruited and compared with a control group of 107 subjects in the general population. Results: Drug users born in north-eastern Italy have a prevalence of anti-HAV similar to the control group. A much higher prevalence was found in drug users born in southern Italy. Conclusion: The similar prevalence of anti-HAV in drug users born in north-eastern Italy and in the general population, suggests that their lifestyle does not involve a substantial additional risk of HAV. The much higher prevalence found in drug users born in southern Italy is more likely to be related to infection during infancy.


  • Open Access

    Immunogenicity, reactogenicity and adherence with hepatitis A vaccination among drug users

    by Gianluca Quaglio, Benedetta Pajusco, Paolo Civitelli, Sabrina Migliozzi, Don C. Des Jarlais, Luisa Romanò, Alessandro Lechi, Paolo Mezzelani, Fabio Lugoboni


  • Hepatitis C virus infection: prevalence, predictor variables and prevention opportunities among drug users in Italy

    by G. L. Quaglio, F. Lugoboni, B. Pajusco, M. Sarti, G. Talamini, Gics, P. Mezzelani, D. C. Des Jarlais

    Summary. The study assessed rates and predictor variables of hepatitis C virus (HCV) infection among drug users receiving pharmacological treatment for opiates addiction.There was a large cohort study in 16 public centres for drug users in north‐eastern Italy, with data collected by standardized face‐to‐face interviews between February 2001 and August 2001.Of 1095 participants, 74.2% were HCV seropositive. Anti‐HCV status was independently associated with duration of drug use of over 10 years, injecting as a route of drug administration, and hepatitis B virus (HBV) and human immunodeficiency virus (HIV) seropositivity. Further statistical analysis was conducted by dividing the subjects on the basis of the duration of heroin use: more or <10 years. In the multivariate analyses, route of drug administration and HBV status were associated with HCV seropositivity among both groups. Less education was associated with HCV among the shorter term drug users. HIV status and having a sexual partner with a history of drug use were associated with HCV seropositivity among the longer term drug users.Half of the short‐term heroin users were still HCV seronegative when starting treatment, suggesting opportunities for reducing new HCV infections. Remarkable was the relationship between vaccination for hepatitis B and HCV serostatus. Being HBV seropositive was strongly associated with being HCV seropositive. But heroin users who had been vaccinated for HBV were not significantly more likely to be HCV seropositive than heroin users who were HBV seronegative. HBV vaccination does not provide biological protection against HCV; however, vaccinating heroin users against HBV may help to create a stronger pro‐health attitude among heroin users, leading to a reduction in HCV risk behaviour.


  • Open Access

    Factors Associated with Hepatitis C Virus Infection in Injection and Noninjection Drug Users in Italy

    by Gianluca Quaglio, Fabio Lugoboni, Benedetta Pajusco, Maddalena Sarti, Giorgio Talamini, Alessandro Lechi, Paolo Mezzelani, Don C. Des Jarlais

    We describe the prevalence of hepatitis C virus (HCV) infection among noninjection users of heroin in Italy and compare the prevalence of HCV infecti


  • Open Access

    Causas principales de muerte entre 2.708 heroinómanos del noreste italiano (1985-1998)

    by G Quaglio, G Talamini, F Lugoboni, A Lechi, L Venturini, Gics Gics, P Mezzelani

    Objetivos. Establecer las causas de la muerte acaecidas entre 1985 y 1998 en un numeroso grupo de usuarios de droga por vía intravenosa (ADVP)] acogidos en 36 Servicios Públicos para Toxicomanías (Ser T) del noroeste italiano. Métodos. Estudio realizado sobre datos recogidos en los archivos de los Ser. T y del Registro Municipal de cada una de las ULSS estudiadas. Individuos implicados. Todos los ADVP que hayan pasado por lo menos una vez por uno de los 36 Ser.T. incluidos en el estudio. Resultados. El estudio analizó las causas de la muerte de 2708 individuos. La primera causa de muerte es la sobredosis (37%), seguida del SIDA (32.5%) y de los accidentes de tráfico (9.4%). El porcentaje de muertes causadas por el SIDA aumentó progresivamente, pasando de un 2.7% en 1985 a un 42.2% en 1996, reduciéndose después al 16.9% en 1998. El porcentaje de fallecimientos por sobredosis se mantuvo prácticamente constante durante todo el tiempo. La edad media de la muerte aumentó, pasando de 26 años a mediados de los años 80 a 34 años en 1998. La tasa de mortalidad entre ADVP es 13 veces mayor que en el conjunto de la población (95%, CI 11.3-14.6). En el conjunto de la población el porcentaje de fallecimientos en edades comprendidas entre los 15 y los 34 años atribuida al uso de opiáceos era en 1991 (año del último censo) del 16%. La prevalencia del VIH no resultó estadísticamente significativa en las causas de muerte por suicidio o sobredosis. Conclusiones. Se comprobó que la tasa de mortalidad era 13 veces superior a la de la población general. Se demostró la importancia del sexo femenino y el drop out de los tratamientos (al margen del tipo de tratamiento en cuestión) como factores de riesgo de sobredosis. La paulatina disminución de muertes por SIDA destaca la importancia de los tratamientos preventivos y terapéuticos adecuados contra la infección de VHC. Las medidas que se adopten en el campo de las drogodependencias, tanto en el ámbito de la política como en la investigación y la formación, deben tener presente el dramáticamente elevado porcentaje de individuos que mueren por consumo de heroína.

    • 31 August 2000
      • Vol. 24  (3) , 120-2

    [Guidelines on drug donations are not sufficient for effective coordination: the case of Mostar in former Yugoslavia].

    by G Quaglio, P Mezzelani, P Procacci, C Cuchillo

    This article deals with the problem of restoring and repairing the supply and distribution of drugs, a vital service damaged by long-term conflicts. During the post-war situation in Bosnia the Authors have been actively involved in the implementation of the Drugs Management Programme whose principal aims were as follows: 1) rationalise the arrival and storage of new drugs; 2) utilise efficiently the stocks of drugs and medical materials at hand; 3) cope with the steady post-war decrease of humanitarian aid drug donations; 4) eliminate the large quantities of expired or inappropriate drugs. The experience stresses the need that all EU countries adopt as far as possible the strict WHO guidelines in their donations to countries in emergency situations. However a very flexible organisation should be set up immediately after the conflict in order to tackle all the problems that, no doubt, will appear in the aftermath of a war.

  • Medical evacuation in war-torn countries

    by Gl Quaglio, P Mezzelani

    • 1 September 1994
      • Vol. 85  (9) , 419-24

    [The significance of the isolated anti-HBc carrier. A study of 1797 drug addicts. The Intersert Group of Scientific Collaboration].

    by P Mezzelani, G Quaglio, L Venturini, F Lugoboni

    From 1985 through 1992 the following hepatitis B markers HBsAg, anti-HBs and anti-HBc were evaluated in 1797 injecting drug users (IDUs) attending 8 Centers for drug addicts in the Veneto region (north-east Italy). Among all IDUs, 1004 (56%) proved to be positive for at least one of the above markers. In particular our aim was to study the carriers of only anti-HBc. At entry, among these 1004 IDUs, 294 (29%) showed only the anti-HBc; 141 IDUs of them have been followed for a period of time: 77% remained without any marker change and 23% showed the appearance of anti-HBs. Subsequently, other 75 IDUs became carrier only of the anti HBc, for the following reasons: loss of anti-HBs (57%) or HBsAg (15%) appearance only of anti-HBc (28%). No carrier of only anti-HBc seroconverted for HBsAg. The evaluation of our data supports the hypothesis that the carrier status of the only anti-HBc prevents from reinfection by HBV and therefore these subjects do not need vaccination.